Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

✍ Scribed by Zeidan, Amer M.; Lee, Ju-Whei; Prebet, Thomas; Greenberg, Peter; Sun, Zhuoxin; Juckett, Mark; Smith, Mitchell R.; Paietta, Elisabeth; Gabrilove, Janice; Erba, Harry P.; Katterling, Rhett P.; Tallman, Martin S.; Gore, Steven D.

• Book ID: 127117902
• Publisher: John Wiley and Sons
• Year: 2014
• Tongue: English
• Weight: 201 KB
• Volume: 167
• Category: Article
• ISSN: 0007-1048
• DOI: 10.1111/bjh.13008